SCHEMBL4897250

SCHEMBL4897250

CCc1nc(NC(=O)c2ccc(Cl)cc2Cl)c(C(=O)OC(C)(C)C)n1-c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.44
CNR2 P34972 3/20 0.44
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
RAB9A P51151 5/20 0.39
NPC1 O15118 4/20 0.39
ALDH1A1 P00352 2/20 0.39
THRB P10828 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
TP53 P04637 1/20 0.38
NTRK1 P04629 1/20 0.38
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ATM Q13315 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4787054 0.88 LMNA (0.46) CNR1CNR2LMNARAB9ANPC1
SCHEMBL4786438 0.87 CNR1 (0.43) CNR1CNR2LMNARAB9ANPC1
SCHEMBL14045306 0.78 LMNA (0.37) CNR2LMNAHPGDALDH1A1TP53
SCHEMBL4786501 0.77 MEN1 (0.35) CNR1CNR2LMNAHPGDRAB9A
SCHEMBL4886940 0.77 MEN1 (0.35) CNR1CNR2LMNAHPGDRAB9A
SCHEMBL4787971 0.76 MEN1 (0.38) LMNAHPGDRAB9ANPC1ALDH1A1
SCHEMBL3441830 0.75 KMT2A (0.40) HPGDNTRK1MEN1KMT2A
SCHEMBL4788948 0.75 KMT2A (0.43) CNR1CNR2LMNARAB9ANPC1
SCHEMBL4859820 0.74 MAPK1 (0.42) CNR1CNR2LMNAALOX15RAB9A
SCHEMBL4885880 0.73 CNR1 (0.39) CNR1CNR2HPGDRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080262064-A1 Novel Compounds For The Treatment Of GI Disorders 682 ASTRAZENECA AB (SE) 2008-10-23 US claimed
US-20080262064-A1 Novel Compounds For The Treatment Of GI Disorders 682 ASTRAZENECA AB (SE) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262064-A1 Novel Compounds For The Treatment Of GI Disorders 682 GABRB2, GABRA2, GABBR2 CNR1 82/4885CNR2 54/4885LMNA 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.